Analysts Anticipate 10x Genomics, Inc. (NASDAQ:TXG) to Post -$0.37 EPS

Equities research analysts expect 10x Genomics, Inc. (NASDAQ:TXGGet Rating) to report earnings per share (EPS) of ($0.37) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for 10x Genomics’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.51). 10x Genomics reported earnings of ($0.11) per share during the same quarter last year, which would indicate a negative year over year growth rate of 236.4%. The company is scheduled to report its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that 10x Genomics will report full-year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($0.96) to ($0.35). For the next year, analysts anticipate that the firm will post earnings of ($0.32) per share, with EPS estimates ranging from ($1.44) to $0.53. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for 10x Genomics.

10x Genomics (NASDAQ:TXGGet Rating) last posted its earnings results on Wednesday, February 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.10). 10x Genomics had a negative net margin of 11.87% and a negative return on equity of 7.38%. The business had revenue of $143.53 million for the quarter, compared to analysts’ expectations of $148.50 million. During the same period last year, the firm posted ($0.08) earnings per share. 10x Genomics’s quarterly revenue was up 27.9% on a year-over-year basis.

TXG has been the topic of a number of research analyst reports. Cowen decreased their target price on 10x Genomics from $205.00 to $145.00 in a research report on Thursday, February 17th. Citigroup lowered their price objective on 10x Genomics from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Zacks Investment Research raised shares of 10x Genomics from a “sell” rating to a “hold” rating in a research report on Thursday, February 17th. Finally, The Goldman Sachs Group lowered their price target on shares of 10x Genomics from $95.00 to $85.00 and set a “neutral” rating for the company in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $135.71.

In other 10x Genomics news, insider Benjamin J. Hindson sold 360 shares of the company’s stock in a transaction dated Tuesday, February 22nd. The shares were sold at an average price of $78.59, for a total transaction of $28,292.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Serge Saxonov sold 12,000 shares of 10x Genomics stock in a transaction that occurred on Tuesday, February 8th. The stock was sold at an average price of $89.90, for a total transaction of $1,078,800.00. The disclosure for this sale can be found here. Insiders sold 30,199 shares of company stock valued at $2,790,248 over the last ninety days. Corporate insiders own 11.57% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC bought a new stake in shares of 10x Genomics during the 4th quarter valued at $29,000. Covestor Ltd purchased a new position in 10x Genomics during the fourth quarter valued at $32,000. National Bank of Canada FI bought a new stake in 10x Genomics during the fourth quarter valued at about $43,000. CI Investments Inc. bought a new stake in 10x Genomics during the third quarter valued at about $51,000. Finally, Koshinski Asset Management Inc. purchased a new stake in 10x Genomics in the fourth quarter worth about $55,000. Institutional investors and hedge funds own 67.36% of the company’s stock.

Shares of NASDAQ TXG opened at $71.48 on Wednesday. 10x Genomics has a 1 year low of $54.72 and a 1 year high of $208.99. The stock has a market capitalization of $8.07 billion, a P/E ratio of -137.46 and a beta of 1.68. The company’s 50-day moving average is $76.38 and its 200 day moving average is $118.68.

About 10x Genomics (Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Read More

Get a free copy of the Zacks research report on 10x Genomics (TXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.